Role of the microbiome in the normal and aberrant glycemic response

Clinical Nutrition Experimental

Volumn 6, Issue , 2016, Pages 59-73

  Suez, Jotham ^a   Shapiro, Hagit ^a   Elinav, Eran ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Diabetes Mellitus; Glucose; Microbiome

Indexed keywords

AMPICILLIN; BILE ACID; COLISTIN; COTRIMOXAZOLE; METRONIDAZOLE; NEOMYCIN; PREBIOTIC AGENT; PROBIOTIC AGENT; SHORT CHAIN FATTY ACID; STREPTOMYCIN; VANCOMYCIN;

ACTINOBACTERIA; AKKERMANSIA MUCINIPHILA; ANAEROCOCCUS; ANTIBIOTIC THERAPY; ARTICLE; BACTEROIDETES; BARIATRIC SURGERY; CIRCADIAN RHYTHM; CLOSTRIDIA; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE ASSOCIATION; ENDOTOXEMIA; ESCHERICHIA COLI; FECAL MICROBIOME TRANSPLANTATION; FIRMICUTES; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INTESTINE FLORA; JET LAG; LACTOBACILLUS; LIPID DIET; LOW CALORY DIET; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PEPTONIPHILUS; POPULATION ABUNDANCE; PREGNANCY; PREVOTELLA; PROTEOBACTERIA; TRANSPLANTATION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84962921782     PISSN: 23529393     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yclnex.2016.01.001     Document Type: Article

References (103)

1. Alberti K.G.M.M., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., et al. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
2. Wen L., Ley R.E., Volchkov P.Y., Stranges P.B., Avanesyan L., Stonebraker A.C., et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008, 455:1109-1113.
3. King C., Sarvetnick N. The incidence of type-1 diabetes in NOD mice is modulated by restricted flora not germ-free conditions. PLoS One 2011, 6. e17049.
4. Kriegel M.A., Sefik E., Hill J.A., Wu H.J., Benoist C., Mathis D. Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proc Natl Acad Sci 2011, 108:11548-11553.
5. Burrows M.P., Volchkov P., Kobayashi K.S., Chervonsky A.V. Microbiota regulates type 1 diabetes through Toll-like receptors. Proc Natl Acad Sci 2015, 112:9973-9977.
6. Brown K., Godovannyi A., Ma C., Zhang Y., Ahmadi-Vand Z., Dai C., et al. Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in Q5 NOD mice. ISME J 2015, 10(2):321-332.
7. Markle J.G.M., Frank D.N., Mortin-Toth S., Robertson C.E., Feazel L.M., Rolle-Kampczyk U., et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science 2013, 339:1084-1088.
8. Yurkovetskiy L., Burrows M., Khan A.A., Graham L., Volchkov P., Becker L., et al. Gender bias in autoimmunity is influenced by microbiota. Immunity 2013, 39:400-412.
9. Alam C., Bittoun E., Bhagwat D., Valkonen S., Saari A., Jaakkola U., et al. Effects of a germ-free environment on gut immune regulation and diabetes progression in non-obese diabetic (NOD) mice. Diabetologia 2011, 54:1398-1406.
10. Lau K., Benitez P., Ardissone A., Wilson T.D., Collins E.L., Lorca G., et al. Inhibition of type 1 diabetes correlated to a Lactobacillus johnsonii N6. 2-mediated Th17 bias. J Immunol 2011, 186:3538-3546.
11. Giongo A., Gano K.A., Crabb D.B., Mukherjee N., Novelo L.L., Casella G., et al. Toward defining the autoimmune microbiome for type 1 diabetes. ISME J 2011, 5:82-91.
12. Brown C.T., Davis-Richardson A.G., Giongo A., Gano K.A., Crabb D.B., Mukherjee N., et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PloS One 2011, 6. e25792.
13. Murri M., Leiva I., Gomez-Zumaquero J.M., Tinahones F.J., Cardona F., Soriguer F., et al. Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC Med 2013, 11:46.
14. Kostic A.D., Gevers D., Siljander H., Vatanen T., Hyötyläinen T., Hämäläinen A.M., et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host Microbe 2015, 17:260-273.
15. Le Chatelier E., Nielsen T., Qin J., Prifti E., Hildebrand F., Falony G., et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013, 500:541-546.
16. Larsen N., Vogensen F.K., van den Berg F.W.J., Nielsen D.S., Andreasen A.S., Pedersen B.K., et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PloS One 2010, 5:e9085.
17. Qin J., Li Y., Cai Z., Li S., Zhu J., Zhang F., et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012, 490:55-60.
18. Karlsson F.H., Tremaroli V., Nookaew I., Bergström G., Behre C.J., Fagerberg B., et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013, 498:99-103.
19. Korem T., Zeevi D., Suez J., Weinberger A., Avnit-Sagi T., Pompan-Lotan M., et al. Growth dynamics of gut microbiota in health and disease inferred from single metagenomic samples. Science 2015, 349:1101-1106.
20. Forslund K., Hildebrand F., Nielsen T., Falony G., Le Chatelier E., Sunagawa S., et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015, 528:262-266.
21. Costello E.K., Lauber C.L., Hamady M., Fierer N., Gordon J.I., Knight R. Bacterial community variation in human body habitats across space and time. Science 2009, 326:1694-1697.
22. Candon S., Perez-Arroyo A., Marquet C., Valette F., Foray A.P., Pelletier B., et al. Antibiotics in early life alter the gut microbiome and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes. PloS One 2015, 10. e0125448.
23. Boursi B., Mamtani R., Haynes K., Yang Y.X. The effect of past antibiotic exposure on diabetes risk. Eur J Endocrinol 2015, 172:639-648.
24. Mikkelsen K.H., Knop F.K., Frost M., Hallas J., Pottegård A. Use of antibiotics and risk of type 2 diabetes: a population-based case-control study. J Clin Endocrinol Metab 2015, 100:3633-3640.
25. Muller L.M., Gorter K.J., Hak E., Goudzwaard W.L., Schellevis F.G., Hoepelman A.I.M., et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005, 41:281-288.
26. David L.A., Maurice C.F., Carmody R.N., Gootenberg D.B., Button J.E., Wolfe B.E., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2013, 505(7484):559-563.
27. Turnbaugh P.J., Ridaura V.K., Faith J.J., Rey F.E., Knight R., Gordon J.I. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 2009, 1. 6ra14.
28. De Filippo C., Cavalieri D., Di Paola M., Ramazzotti M., Poullet J.B., Massart S., et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci 2010, 107:14691-14696.
29. Hildebrandt M.A., Hoffmann C., Sherrill-Mix S.A., Keilbaugh S.A., Hamady M., Chen Y.Y., et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009, 137:1716-1724.
30. Turnbaugh P.J., Bäckhed F., Fulton L., Gordon J.I. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008, 3:213-223.
31. Cani P.D., Bibiloni R., Knauf C., Waget A., Neyrinck A.M., Delzenne N.M., et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008, 57:1470-1481.
32. Caesar R., Tremaroli V., Kovatcheva-Datchary P., Cani P.D., Backhed F. Crosstalk between gut microbiota and dietary lipids aggravatesWAT inflammation through TLR signaling. Cell Metab 2015, 22:658-668.
33. Ley R.E., Turnbaugh P.J., Klein S., Gordon J.I. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
34. Gardner C., Wylie-Rosett J., Gidding S.S., Steffen L.M., Johnson R.K., Reader D., et al. Nonnutritive sweeteners: current use and health perspectives a scientific statement from the American heart association and the American diabetes association. Diabetes care 2012, 35:1798-1808.
35. Suez J., Korem T., Zilberman-Schapira G., Segal E., Elinav E. Non-caloric artificial sweeteners and the microbiome: findings and challenges. Gut Microbes 2015, 6:149-155.
36. Suez J., Korem T., Zeevi D., Zilberman-Schapira G., Thaiss C.A., Maza O., et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature 2014, 514:181-186.
37. Palmnäs M.S.A., Cowan T.E., Bomhof M.R., Su J., Reimer R.A., Vogel H.J., et al. Low-dose aspartame consumption differentially affects gut microbiota-host metabolic interactions in the diet-induced obese rat. PloS One 2014, 9. e109841.
38. Chassaing B., Koren O., Goodrich J.K., Poole A.C., Srinivasan S., Ley R.E., et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 2015, 519:92-96.
39. Koren O., Goodrich J.K., Cullender T.C., Spor A., Laitinen K., Bäckhed H.K., et al. Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell 2012, 150:470-480.
40. DiGiulio D.B., Callahan B.J., McMurdie P.J., Costello E.K., Lyell D.J., Robaczewska A., et al. Temporal and spatial variation of the human microbiota during pregnancy. Proc Natl Acad Sci U S A 2015, 112:11060-11065.
41. Henao-Mejia J., Elinav E., Thaiss C.A., Flavell R.A. Inflammasomes and metabolic disease. Annu Rev Physiol 2014, 76:57-78.
42. Konner A.C., Bruning J.C. Toll-like receptors: linking inflammation to metabolism. Trends Endocrinol Metab TEM 2011, 22:16-23.
43. Cani P.D., Amar J., Iglesias M.A., Poggi M., Knauf C., Bastelica D., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
44. Saberi M., Woods N.B., de Luca C., Schenk S., Lu J.C., Bandyopadhyay G., et al. Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab 2009, 10:419-429.
45. Amar J., Chabo C., Waget A., Klopp P., Vachoux C., Bermudez-Humaran L.G., et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011, 3:559-572.
46. Vijay-Kumar M., Aitken J.D., Carvalho F.A., Cullender T.C., Mwangi S., Srinivasan S., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
47. Vandanmagsar B., Youm Y.H., Ravussinn A., Galgani J.E., Stadler K., Mynatt R.L., et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011, 17:179-188.
48. Henao-Mejia J., Elinav E., Jin C., Hao L., Mehal W.Z., Strowig T., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
49. Stienstra R., Joosten L.A., Koenen T., van Tits B., van Diepen J.A., van den Berg S.A., et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 2010, 12:593-605.
50. de La Serre C.B., Ellis C.L., Lee J., Hartman A.L., Rutledge J.C., Raybould H.E. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol 2010, 299:G440-G448.
51. Luck H., Tsai S., Chung J., Clemente-Casares X., Ghazarian M., Revelo X.S., et al. Regulation of obesity-related insulin resistance with gut anti-inflammatory agents. Cell Metab 2015, 21:527-542.
52. Buchwald H., Estok R., Fahrbach K., Banel D., Jensen M.D., Pories W.J., et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009, 122:248-256.
53. Furet J.-P., Kong L.C., Tap J., Poitou C., Basdevant A., Bouillot J.L., et al. Differential Adaptation of human gut microbiota to bariatric surgeryeinduced weight loss links with metabolic and low-grade inflammation markers. Diabetes 2010, 59:3049-3057.
54. Graessler J., Qin Y., Zhong H., Zhang J., Licinio J., Wong M.L., et al. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics J 2013, 13:514-522.
55. Zhang H., DiBaise J.K., Zuccolo A., Kudrna D., Braidotti M., Yu Y., et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci 2009, 106:2365-2370.
56. Kong L.-C., Tap J., Aron-Wisnewsky J., Pelloux V., Basdevant A., Bouillot J.L., et al. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr 2013, 98:16-24.
57. Tremaroli V., Karlsson F., Werling M., Ståhlman M., Kovatcheva-Datchary P., Olbers T., et al. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab 2015, 22:228-238.
58. Thaiss C.A., Zeevi D., Levy M., Zilberman-Schapira G., Suez J., Tengeler A.C., et al. Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. Cell 2014, 159:514-529.
59. Zarrinpar A., Chaix A., Yooseph S., Panda S. Diet and feeding pattern affect the diurnal dynamics of the gut microbiome. Cell Metab 2014, 20:1006-1017.
60. Leone V., Gibbons S.M., Martinez K., Hutchison A.L., Huang E.Y., Cham C.M., et al. Effects of diurnal variation of gut microbes and high-fat feeding on host circadian clock function and metabolism. Cell Host Microbe 2015, 17:681-689.
61. Liang X., Bushman F.D., FitzGerald G.A. Rhythmicity of the intestinal microbiota is regulated by gender and the host circadian clock. Proc Natl Acad Sci 2015, 112:10479-10484.
62. Khan M.T., Nieuwdorp M., Backhed F. Microbial modulation of insulin sensitivity. Cell Metab 2014, 20:753-760.
63. Layden B.T., Angueira A.R., Brodsky M., Durai V., Lowe W.L. Short chain fatty acids and their receptors: new metabolic targets. Transl Res J Lab Clin Med 2013, 161:131-140.
64. De Vadder F., Kovatcheva-Datchary P., Goncalves D., Vinera J., Zitoun C., Duchampt A., et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014, 156:84-96.
65. Donohoe D.R., Garge N., Zhang X., Sun W., O'Connell T.M., Bunger M.K., et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab 2011, 13:517-526.
66. Tolhurst G., Heffron H., Lam Y.S., Parker H.E., Habib A.M., Diakogiannaki E., et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 2012, 61:364-371.
67. Wichmann A., Allahyar A., Greiner T.U., Plovier H., Lunden G.O., Larsson T., et al. Microbial modulation of energy availability in the colon regulates intestinal transit. Cell Host Microbe 2013, 14:582-590.
68. Kimura I., Ozawa K., Inoue D., Imamura T., Kimura K., Maeda T., et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun 2013, 4:1829.
69. Maslowski K.M., Vieira A.T., Ng A., Kranich J., Sierro F., Yu D., et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009, 461:1282-1286.
70. Brestoff J.R., Artis D. Immune regulation of metabolic homeostasis in health and disease. Cell 2015, 161:146-160.
71. Ganapathy V., Thangaraju M., Prasad P.D., Martin P.M., Singh N. Transporters and receptors for short-chain fatty acids as the molecular link between colonic bacteria and the host. Curr Opin Pharmacol 2013, 13:869-874.
72. Candido E.P., Reeves R., Davie J.R. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 1978, 14:105-113.
73. Ridlon J.M., Kang D.J., Hylemon P.B. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006, 47:241-259.
74. Thomas C., Pellicciari R., Pruzanski M., Auwerx J., Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008, 7:678-693.
75. Chiang J.Y. Bile acids: regulation of synthesis. J Lipid Res 2009, 50:1955-1966.
76. Claus S.P., Tsang T.M., Wang Y., Cloarec O., Skordi E., Martin F.P., et al. Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol Syst Biol 2008, 4:219.
77. Kuribayashi H., Miyata M., Yamakawa H., Yoshinari K., Yamazoe Y. Enterobacteria-mediated deconjugation of taurocholic acid enhances ileal farnesoid X receptor signaling. Eur J Pharmacol 2012, 697:132-138.
78. Sayin S.I., Wahlstrom A., Felin J., Jantti S., Marschall H.U., Bamberg K., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013, 17:225-235.
79. Swann J.R., Want E.J., Geier F.M., Spagou K., Wilson I.D., Sidaway J.E., et al. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci 2011, 108(Suppl. 1):4523-4530.
80. Ridaura V.K., Faith J.J., Rey F.E., Cheng J., Duncan A.E., Kau A.L., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013, 341:1241214.
81. Zhang Y., Ge X., Heemstra L.A., Chen W.D., Xu J., Smith J.L., et al. Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice. Mol Endocrinol 2012, 26:272-280.
82. Li T., Owsley E., Matozel M., Hsu P., Novak C.M., Chiang J.Y. Transgenic expression of cholesterol 7alpha-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology 2010, 52:678-690.
83. Ryan K.K., Tremaroli V., Clemmensen C., Kovatcheva-Datchary P., Myronovych A., Karns R., et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 2014, 509:183-188. 2015;163:1428-43.
84. Levy M., Thaiss C.A., Zeevi D., Dohnalova L., Zilberman-Schapira G., Mahdi J.A., et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell 2015, 163:1428-1443.
85. Creely S.J., McTernan P.G., Kusminski C.M., Fisher F.M., Da Silva N.F., Khanolkar M., et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007, 292:E740-E747.
86. Carvalho B.M., Guadagnini D., Tsukumo D.M.L., Schenka A.A., Latuf-Filho P., Vassallo J., et al. Modulation of gut microbiota by antibiotics improves insulin signalling in high-fat fed mice. Diabetologia 2012, 55:2823-2834.
87. Caesar R., Reigstad C.S., Backhed H.K., Reinhardt C., Ketonen M., Lunden G.O., et al. Gut-derived lipopolysaccharide augments adipose macrophage accumulation but is not essential for impaired glucose or insulin tolerance in mice. Gut 2012, 61:1701-1707.
88. Membrez M., Blancher F., Jaquet M., Bibiloni R., Cani P.D., Burcelin R.G., et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008, 22:2416-2426.
89. Hara N., Alkanani A.K., Ir D., Robertson C.E., Wagner B.D., Frank D.N., et al. Prevention of virus-induced type 1 diabetes with antibiotic therapy. J Immunol 2012, 189:3805-3814.
90. Vrieze A., Out C., Fuentes S., Jonker L., Reuling I., Kootte R.S., et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol 2014, 60:824-831.
91. Ayres J.S., Trinidad N.J., Vance R.E. Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the microbiota. Nat Med 2012, 18:799-806.
92. Vrieze A., Van Nood E., Holleman F., Salojärvi J., Kootte R.S., Bartelsman J.F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012, 143:913-916.
93. Gao Z., Yin J., Zhang J., Ward R.E., Martin R.J., Lefevre M., et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009, 58:1509-1517.
94. Calcinaro F., Dionisi S., Marinaro M., Candeloro P., Bonato V., Marzotti S., et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 2005, 48:1565-1575.
95. Andersson U., Bränning C., Ahrné S., Molin G., Alenfall J., Önning G., et al. Probiotics lower plasma glucose in the high-fat fed C57BL/6J mouse. Benef Microbes 2010, 1:189-196.
96. Andreasen A.S., Larsen N., Pedersen-Skovsgaard T., Berg R.M., Møller K., Svendsen K.D., et al. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br J Nutr 2010, 104:1831-1838.
97. Ruan Y., Sun J., He J., Chen F., Chen R., Chen H. Effect of probiotics on glycemic control: a systematic review and meta-analysis of randomized, controlled trials. PloS One 2015, 10. e0132121.
98. Shin N.R., Lee J.C., Lee H.Y., Kim M.S., Whon T.W., Lee M.S., et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 2013, 63(5):727-735.
99. Everard A., Belzer C., Geurts L., Ouwerkerk J.P., Druart C., Bindels L.B., et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci 2013, 110:9066-9071.
100. Chen Z., Guo L., Zhang Y., Walzem R.L., Pendergast J.S., Printz R.L., et al. Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. J Clin Investig 2014, 124(8):3391-3406.
101. Cani P.D., Neyrinck A.M., Fava F., Knauf C., Burcelin R.G., Tuohy K.M., et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007, 50:2374-2383.
102. Zeevi D., Korem T., Zmora N., Israeli D., Rothschild D., Weinberger A., et al. Personalized nutrition by prediction of glycemic responses. Cell 2015, 163:1079-1094.
103. Kovatcheva-Datchary P., Nilsson A., Akrami R., Lee Y.S., De Vadder F., Arora T., et al. Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of prevotella. Cell Metab 2015, 22(6):971-982.